Omnia SanaPlant Comparison
Perforate St John’s-wort vs Catnip
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Perforate St John’s-wort and Catnip: they share 6 indicated uses (arthritis / joint pain, infection (general), inflammation (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Perforate St John’s-wort | Catnip | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Infection (general) | 1/10 | 2/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Insomnia / sleeplessness | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
| Wounds | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.
Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.
Antioxidant flavonoids contributing to overall activity.
The characteristic volatile iridoid responsible for the cat-attractant effect and studied for sedative, antimicrobial and insect-repellent activity.
Rich in nepetalactone isomers along with other monoterpenes; studied for antimicrobial and antioxidant activity.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from antiviral action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from digestive action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.
Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).
Pregnancy: Do not use (traditional concern around stimulating menstruation/uterus) (Health Canada, n.d.). Breastfeeding: Health Canada advises talk to a healthcare professional first (Health Canada, n.d.). Kids: It’s often described as a “gentle” traditional tea, but large amounts are not a good idea—there’s a published case where a toddler became very sleepy/“slowed down” after consuming a lot. Keep catnip tea away from toddlers unless a clinician advises it (Osterhoudt et al., 1997). Sedatives / alcohol: Catnip can be calming, so don’t stack it with other sedating herbs/sleep meds/alcohol (you could get extra drowsy) (WebMD, n.d.a). Essential oil caution: Catnip essential oil is concentrated. Research notes it may cause mild skin irritation for some people—always dilute, patch test, and never treat it like “tea.” (Reichert et al., 2019)
Duke (2002) describes catnip primarily as a sedative, diaphoretic, and emmenagogue with experimental (score 1) support. It has demonstrated uterotonic and oxytocic activity, making it contraindicated in pregnancy. The active compounds include nepetalactone and iridoids. Catnip is classified as a mild nervine and antispasmodic in traditional North American herbal medicine, though clinical trials are lacking. Due to its emmenagogue and uterotonic properties, medicinal-dose use should be avoided during pregnancy (Duke, 2002).
External Ids
Botanical Description
Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]
Perennial herb, 30-100 cm tall, with greyish-green, downy, square stems typical of the mint family. Leaves are opposite, triangular-ovate with scalloped or toothed margins, grey-green above and softly felted (whitish) beneath, releasing a minty-lemony aroma when crushed. Small white flowers, spotted with purple or pink, are borne in dense terminal and axillary spikes. Nepetalactone, the volatile compound famous for its effect on cats, is concentrated in glandular hairs on the leaves and stems.[9]
Habitat
Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]
Native to Europe and temperate Asia and widely naturalised in North America; grows on disturbed, sunny ground - roadsides, waste places, hedgebanks and dry, calcareous or well-drained soils.[9]
Harvesting
The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]
Traditional Uses
St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]
Catnip has a long North American and European folk-medicine history as a mild sedative/nervine, diaphoretic (fever-reducing, sweat-promoting) remedy, carminative digestive and traditional emmenagogue; it was also given as a children's tea for colic and restlessness, though large amounts are not advised for young children and it is traditionally avoided in pregnancy.[9]
Preparations
Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.
Dosage
Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.
Health Canada's NNHPD monograph gives 1.2-12 g of dried herb top per day for adults 18 years and older, with infusion among the accepted methods of preparation. Educational reference only, not a prescription. Keep away from toddlers and young children beyond very small amounts, and avoid medicinal-dose use in pregnancy.
Drug Class Interactions
References
Pairings
St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]
St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]
St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]
St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]
Not documented
Lookalikes Review
References & Sources
- Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
https://doi.org/10.1016/j.jad.2016.12.048 - Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
https://doi.org/10.1007/s00210-022-02229-z - Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
https://doi.org/10.1016/S0140-6736(99)06457-0 - Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
https://doi.org/10.22038/IJBMS.2022.65112.14338 - Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
https://doi.org/10.1016/j.phymed.2024.155847 - Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
https://doi.org/10.3389/fpls.2016.01004 - Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
https://doi.org/10.1002/ptr.5050 - Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
https://doi.org/10.1016/j.jep.2010.07.034 - Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
https://doi.org/10.1016/j.lfs.2004.04.005 - Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
https://doi.org/10.3109/13697137.2013.861814 - Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
https://doi.org/10.2165/00003088-200645050-00002 - Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
https://doi.org/10.1055/s-2001-15467 - Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
https://doi.org/10.1038/sj.mp.4000557 - Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
https://doi.org/10.2174/1568026033392589 - Linde, K. et al (2008) 'St John'. Traditional / reference
https://scholar.google.com/scholar?q=St%20John - Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
https://doi.org/10.1177/0269881104042632 - Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
https://doi.org/10.2165/11317010-000000000-00000 - Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
https://doi.org/10.1208/s12248-009-9146-8 - Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
https://doi.org/10.1111/bph.14936 - Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
https://doi.org/10.1016/S0140-6736(99)05712-8 - Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
https://doi.org/10.1345/aph.10088 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
https://doi.org/10.1046/j.1365-2125.2003.02005.x - Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
https://doi.org/10.1053/cp.1999.v66.a101944 - Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
https://doi.org/10.1093/jnci/94.16.1247 - Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
https://doi.org/10.1592/phco.24.16.1508.50958 - Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
https://doi.org/10.5414/cpp42139 - Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
https://doi.org/10.3390/ph19030399
- Geissler, M., Neubauer, C., Sheludko, Y.V. and Warzecha, H (2024) 'Nepeta cataria L. (catnip) can serve as a chassis for the engineering of secondary metabolic pathways', Biotechnology Letters, 46(5), pp. 843-850. doi:10.1007/s10529-024-03489-w Preclinical
https://doi.org/10.1007/s10529-024-03489-w - Lockhart, A., Simon, J.E. and Wu, Q (2024) 'Stability study of Nepeta cataria iridoids analyzed by LC/MS', Phytochemical Analysis, 35(7), pp. 1674-1687. doi:10.1002/pca.3410 Preclinical
https://doi.org/10.1002/pca.3410 - Nadeem, A., Shahzad, H., Ahmed, B., Muntean, T. and others (2022) 'Phytochemical profiling of antimicrobial and potential antioxidant plant: Nepeta cataria', Frontiers in Plant Science, 13, pp. 969316. doi:10.3389/fpls.2022.969316 Preclinical
https://doi.org/10.3389/fpls.2022.969316 - Tan, J., Li, J., Ma, J. and Qiao, F (2019) 'Hepatoprotective effect of essential oils of Nepeta cataria L. on acetaminophen-induced liver dysfunction', Bioscience Reports, 39(8), pp. BSR20190697. doi:10.1042/BSR20190697 Preclinical
https://doi.org/10.1042/BSR20190697 - Mollova, S., Dzhurmanski, A., Fidan, H., Bojilov, D. and others (2023) 'Chemical Composition of Essential Oils from Nepeta cataria L. Cultivated in Bulgaria and Their Antimicrobial and Antioxidant Activity', ACS Omega, 8(17), pp. 15441-15449. doi:10.1021/acsomega.3c00704 Preclinical
https://doi.org/10.1021/acsomega.3c00704 - Reichert, W., Ejercito, J., Guda, T., Dong, X. and others (2019) 'Repellency Assessment of Nepeta cataria Essential Oils and Isolated Nepetalactones on Aedes aegypti', Scientific Reports, 9(1), pp. 1524. doi:10.1038/s41598-018-36814-1 Preclinical
https://doi.org/10.1038/s41598-018-36814-1 - Tiwari, G., Chaturvedi, T., Gupta, A.K., Lal, R.K. and others (2023) 'Assessment of Genetic Diversity, Micromorphology and Antimicrobial Activity in Nepeta cataria L', Chemistry & Biodiversity, 20(2), pp. e202200241. doi:10.1002/cbdv.202200241 Preclinical
https://doi.org/10.1002/cbdv.202200241 - Giarratana, F., Muscolino, D., Ziino, G., Lo Presti, V. and others (2017) 'Activity of Catmint (Nepeta cataria) essential oil against Anisakis larvae', Tropical Biomedicine, 34(1), pp. 22-31. Available at: https://pubmed.ncbi.nlm.nih.gov/33592976/ Preclinical
https://pubmed.ncbi.nlm.nih.gov/33592976/ - Sarkar, M., Rashmi, R., Vikramaditya and Varma, P.N (1995) 'Pharmacognosy of Nepeta cataria', Ancient Science of Life, 14(4), pp. 225-234. Available at: https://pubmed.ncbi.nlm.nih.gov/22556702/ Traditional / reference
https://pubmed.ncbi.nlm.nih.gov/22556702/ - Bernardi, M.M., Kirsten, T.B., Lago, J.H.G., Giovani, T.M. and Massoco, C.O (2011) 'Nepeta cataria L. var. citriodora (Becker) increases penile erection in rats', Journal of Ethnopharmacology, 137(3), pp. 1318-1322. doi:10.1016/j.jep.2011.07.061 Preclinical
https://doi.org/10.1016/j.jep.2011.07.061 - Health Canada, Natural and Non-prescription Health Products Directorate (2026) 'Natural Health Product Monograph: Catnip - Nepeta cataria'. Available at: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_catnip_english.pdf Traditional / reference
https://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_catnip_english.pdf - British Herbal Medicine Association (1983) 'British Herbal Pharmacopoeia'. Traditional / reference
https://scholar.google.com/scholar?q=British%20Herbal%20Pharmacopoeia - Gilani, A.H., Shah, A.J., Zubair, A., Khalid, S., Kiani, J., Ahmed, A., Rasheed, M. and Ahmad, V.U (2009) 'Chemical composition and mechanisms underlying the spasmolytic and bronchodilatory properties of the essential oil of Nepeta cataria L', 121(3), pp. 405--411. doi:10.1016/j.jep.2008.11.004 Traditional / reference
https://doi.org/10.1016/j.jep.2008.11.004 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.